Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design
TRPC5通道抑制剂GFB-887在局灶节段性肾小球硬化症、难治性微小病变肾病或糖尿病肾病患者中的安全性和有效性:TRACTION-2试验设计
期刊:Kidney International Reports
影响因子:5.7
doi:10.1016/j.ekir.2021.07.006
Walsh, Liron; Reilly, John F; Cornwall, Caitlin; Gaich, Gregory A; Gipson, Debbie S; Heerspink, Hiddo J L; Johnson, Leslie; Trachtman, Howard; Tuttle, Katherine R; Farag, Youssef M K; Padmanabhan, Krishna; Pan-Zhou, Xin-Ru; Woodworth, James R; Czerwiec, Frank S